Home > News Center
 
Contact Us
Shanghai BravoBio Co., Ltd.
Add:Suite 14E, Building #5, Haifu Garden, 1365 Dongfang Road, Lujiazui Financial and Trade Zone, Shanghai 200127, China
Tel: +86 21 2025 5516
Fax: +86 21 2025 5517
Email: bd@bravobio.com
News Center
 
Type 1 diabetes vaccine shows promise in early study
Jun.27, 2013
 
A new study has suggested a type of vaccine for patients involved in type 1 diabetes that affects on their immune system to stop attacking the body.The study shows that the suggested vaccine can retrain the patient's autoimmune system to protect the cells that make insulin, according to a paper published in the journal Science Translational Medicine.
Made by the researchers at the Stanford University Medical Centre, the vaccine with opposite effect can alter the routine function of the immune system. Researchers dubbed the treatment a "reverse vaccine" because it suppresses the immune system instead of stimulating it.
The vaccine designed to protect beta cells was targeted to the specific white blood cells as killer cells which attack beta cells. Patients in the vaccine group, no matter the dosage, saw the number of killer cells fall and the amount of proinsulin rise over 15 weeks without affecting the rest of their immune system cells. The changes were much more modest in patients who got the placebo.
 
Novavax Announces Positive Top-Line Results From Phase 1 Clinical Trial of RSV Vaccine Candidate in Elderly
Jul. 2, 2013
 
Novavax, Inc. (NVAX) today announced positive top-line safety and immunogenicity data for its respiratory syncytial virus(RSV) vaccine candidate from a dose-ranging Phase 1 study in elderly adults. All subject groups receiving the recombinant fusion (F) protein nanoparticle vaccine candidate exhibited antibody responses against RSV at 28 and 56 days post-immunization, with rises in serum anti-F immunoglobulin G (IgG) antibody levels. The highest response rates and greatest increases in antibody levels were observed in groups receiving RSV F antigen with aluminum phosphate as an adjuvant. All subjects simultaneously received a licensed seasonal trivalent influenza vaccine to ensure coverage over the influenza season. Local and systemic safety were monitored and together with the interim immunogenicity are provided here as top line data through Day 56.
 
Huawei BravoBio granted with High-technology Enterprise Certificate
Jul. 9, 2013
 
The Joint Venture of BravoBio in Beijing, Huawei BravoBio, got its High-technology Enterprise Certificate of Zhongguancun Science Park, the first National Independent Innovation Demonstration Zone in China. This is a Beijing Municipal-level (or provincial-level) certificate and the firm will be benefited from governmental financial support, preferential taxation, etc. subsequently.
 
European Commission approves pneumococcal conjugate vaccine for use in adults
Jul. 10, 2013
 
The European Commission recently approved an expanded indication for the 13-valent pneumococcal conjugate vaccine to include adults aged 18 to 49 years for the prevention of invasive pneumococcal disease caused by vaccine-type Streptococcus pneumoniae.
The pneumococcal conjugate vaccine (PCV13; Prevnar 13, Pfizer) was previously approved in the European Union for use in infants, young children and adolescents aged 6 weeks to 17 years, as well as adults 50 years of age and older.
The decision to approve this label expansion for PCV13 was based on data from an open-label phase 3 trial of the vaccine in healthy adults aged 18 to 49 years. The study showed the vaccine was at least as immunogenic in this age group as it is in adults aged 60 to 64 years, as measured one month after vaccination. PCV13 also showed a favorable safety profile and was generally well tolerated, according to the manufacturer.
PCV13 is marketed as Prevenar in Europe.
 
Findings Offer Alternative Approach to Creating a Universal Influenza Vaccine
Jul. 15, 2013
 
A team of scientists, led by researchers at The Wistar Institute, has determined that it might be possible to stimulate the immune system against multiple strains of influenza virus by sequentially vaccinating individuals with distinct influenza strains isolated over the last century.
Their results also suggest that world health experts might need to re-evaluate standard tests used for surveillance of novel influenza strains. Their findings are published in the Journal of Experimental Medicine, available online now.
According to the Wistar researchers, their analysis could lead to an alternative approach to creating a "universal" flu vaccine -- a vaccine that would provide resistance to seasonal and pandemic influenza strains over many years, negating the need for an annual flu shot.
 
Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16
Jul. 30, 2013
 
Researchers have recently identified six neutralizing linear epitopes of CA16, which could protect mice against lethal hand, foot and mouth disease challenge. Selected from a panel of 95 synthetic peptides spanning the entire VP1 protein of CA16, these 6 peptides neutralized both homologous and heterologous CA16 strains. Sequence alignment also showed that these epitopes are extremely conserved among CA16 strains of different genotypes, which might have important implications for the development of peptide-based broadly protective CA16 vaccines.
 
US FDA expands Novartis' Menveo indication for infants aged two months
Aug. 2, 2013
 
The US Food and Drug Administration (FDA) has expanded age indication for Novartis' Menveo (Meningococcal [Groups A, C, Y and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine) to include infants and toddlers aged two months and more.
Menveo is a quadrivalent conjugate vaccine developed for the prevention of meningococcal disease caused by four strains of the bacterium Neisseria meningitidis (N. meningitidis).
 
Sanofi starts late-stage test for Clostridium vaccine
Aug. 5, 2013
 
Sanofi said on Monday it had started late-stage trials involving 15,000 people to test a vaccine against Clostridium difficile infections (CDI), the main cause of diarrhea in hospitals.
There are currently no vaccines available against the Clostridium difficile bacteria, while increasing antibiotic resistance is making it harder to treat the condition.
Combined data from the United States and European Union show that healthcare systems spend more than $7 billion annually to treat CDI cases.
 
GSK, Pfizer commit more pneumococcal vaccines to Unicef program
Aug. 19, 2013
 
Unicef expects to bring an annual stockpile of 146 million shots of pneumococcal vaccines to about 60 developing countries from 2016-2020, 50 million of which will come from GSK's Synflorix and Pfizer's Prevnar 13, with Pfizer agreeing to a price of $3.30 per dose from 2014. The price will not drop significantly until 2016 when Serum Institute of India hopes to introduce its 10-valent pneumococcal vaccine and help Unicef fill the gap between supply and demand.
Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next